Natural therapeutics and nutraceuticals for lung diseases: Traditional significance, phytochemistry, and pharmacology

Abstrakt

Background Lung diseases including chronic obstructive pulmonary disease (COPD), infections like influenza, acute respiratory distress syndrome (ARDS), asthma and pneumonia lung cancer (LC) are common causes of sickness and death worldwide due to their remoteness, cold and harsh climatic conditions, and inaccessible health care facilities. Purpose Many drugs have already been proposed for the treatment of lung diseases. Few of them are in clinical trials and have the potential to cure infectious diseases. Plant extracts or herbal products have been extensively used as Traditional Chinese Medicine (TCM) and Indian Ayurveda. Moreover, it has been involved in the inhibition of certain genes/protiens effects to promote regulation of signaling pathways. Natural remedies have been scientifically proven with remarkable bioactivities and are considered a cheap and safe source for lung disease. Methods This comprehensive review highlighted the literature about traditional plants and their metabolites with their applications for the treatment of lung diseases through experimental models in humans. Natural drugs information and mode of mechanism have been studied through the literature retrieved by Google Scholar, ScienceDirect, SciFinder, Scopus and Medline PubMed resources against lung diseases. Results In vitro, in vivo and computational studies have been explained for natural metabolites derived from plants (like flavonoids, alkaloids, and terpenoids) against different types of lung diseases. Probiotics have also been biologically active therapeutics against cancer, anti-inflammation, antiplatelet, antiviral, and antioxidants associated with lung diseases. Conclusion The results of the mentioned natural metabolites repurposed for different lung diseases especially for SARS-CoV-2 should be evaluated more by advance computational applications, experimental models in the biological system, also need to be validated by clinical trials so that we may be able to retrieve potential drugs for most challenging lung diseases especially SARS-CoV-2.

Autorzy

Mominur Rahman
Mominur Rahman
Shabana Bibi
Shabana Bibi
Saidur Rahaman
Saidur Rahaman
Firoza Rahman
Firoza Rahman
Fahadul Islam
Fahadul Islam
Muhammad S. Khan
Muhammad S. Khan
Mohammad M. Hasan
Mohammad M. Hasan
Anwar Parvez
Anwar Parvez
Abid Hossain
Abid Hossain
Saila K. Maeesa
Saila K. Maeesa
Rezaul Islam
Rezaul Islam
Hamdan S. Al-Malky
Hamdan S. Al-Malky
Hanan R. H. Mohamed
Hanan R. H. Mohamed
Hussah I.M. Algwaiz
Hussah I.M. Algwaiz
Aeshah A. Awaji
Aeshah A. Awaji
Mousa O. Germoush
Mousa O. Germoush
Osama A. Kensara
Osama A. Kensara
Mohamed M. Abdel-Daim
Mohamed M. Abdel-Daim
Mohd Saeed
Mohd Saeed
Mohammad A. Kamal
Mohammad A. Kamal
artykuł
BIOMEDICINE & PHARMACOTHERAPY
Angielski
2022
150
113041
otwarte czasopismo
CC BY-NC-ND Uznanie autorstwa-Użycie niekomercyjne-Bez utworów zależnych 4.0
ostateczna wersja opublikowana
w momencie opublikowania
2022-05-06
100
7,5
0
43